StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research report report published on Tuesday morning. The brokerage issued a sell rating on the stock.
Separately, Cantor Fitzgerald reaffirmed an overweight rating and issued a $2.50 price objective on shares of VolitionRx in a research note on Thursday, May 16th.
Check Out Our Latest Stock Analysis on VolitionRx
VolitionRx Trading Up 10.1 %
VolitionRx (NYSE:VNRX – Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $0.17 million for the quarter, compared to analysts’ expectations of $0.27 million. On average, equities analysts forecast that VolitionRx will post -0.31 earnings per share for the current fiscal year.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Recommended Stories
- Five stocks we like better than VolitionRx
- What Are the FAANG Stocks and Are They Good Investments?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Stock Average Calculator
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.